Ge Jie, Liu Ting, Lei Tianxiang, Li Xuan, Song Kun, Azizi Samim, Liu Heli, Tang Mimi
Department of Gastrointestinal Surgery, Xiangya Hospital, Central South University, Changsha, China.
Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China.
Front Pharmacol. 2021 Apr 13;12:659258. doi: 10.3389/fphar.2021.659258. eCollection 2021.
5-fluorouracil (5-FU) is basically used in the field of postoperative chemotherapy of gastric cancer (GC), the goal of this study was to evaluate improvement of long-term survival rate among GC patients after the 5-FU implants treatment. The study included 145 patients with gastric cancer who received postoperative chemotherapy with 5-FU implants and had complete follow-up information. According to the sex, age and clinical stage of 5-FU implants group, 74 patients were matched as the control group at the same time. In the study, we compared the 5-year overall survival rate with progression-free survival rate in the two groups, and the drug safety for both groups during the treatment was also compared. The median follow-up time was 85 months (range 60-116 months). 31 patients (21.38%) died of tumor recurrence in 5-FU implants group and 21 (28.38%) in control group. In the control group, metastatic lesions were found in the small intestine, left adrenal gland and peritoneum in three patients. The 5-year progression-free survival (PFS) rate was 79.71% in 5-FU group and 67.12% in control ( = 0.0045). The 5-year overall survival (OS) rate was 77.68% in 5-FU implants group and 64.87% in control ( = 0.0159). Both the 5-years OS and PFS rates in 5-FU group were better than control group without significant side effect. 5-FU implants may improve 5-years OS and PFS rates after surgery in gastric cancer patients, while good safety profile suggests it could be reliable.
5-氟尿嘧啶（5-FU）主要用于胃癌（GC）术后化疗领域，本研究的目的是评估5-FU植入治疗后GC患者长期生存率的改善情况。该研究纳入了145例接受5-FU植入术后化疗且有完整随访信息的胃癌患者。根据5-FU植入组的性别、年龄和临床分期，同时匹配74例患者作为对照组。在本研究中，我们比较了两组的5年总生存率和无进展生存率，并比较了两组治疗期间的药物安全性。中位随访时间为85个月（范围60-116个月）。5-FU植入组31例患者（21.38%）死于肿瘤复发，对照组21例（28.38%）。对照组有3例患者在小肠、左肾上腺和腹膜发现转移病灶。5-FU组的5年无进展生存（PFS）率为79.71%，对照组为67.12%（P = 0.0045）。5-FU植入组的5年总生存（OS）率为77.68%，对照组为64.87%（P = 0.0159）。5-FU组的5年OS率和PFS率均优于对照组，且无明显副作用。5-FU植入可能改善胃癌患者术后的5年OS率和PFS率，同时良好的安全性表明其可靠。
